RMTG ISSCA Regenerative Medicine Fellowship Launch
Analysis based on 6 articles · First reported Sep 17, 2026 · Last updated Sep 17, 2026
The announcement is a company-specific press release from a small OTC-listed regenerative medicine firm and is unlikely to move broad markets or major sector indexes. It may draw modest speculative interest in RMTG shares and in the regenerative medicine and medical education niche, but the early-stage nature of ISSCA AI and the absence of disclosed enrollment or revenue figures limit any measurable market effect.
Regenerative Medical Technology Group, Inc. (OTCID:RMTG) announced on September 17, 2026 the launch, through its ISSCA division, of a new Integrative Fellowship in Point-of-Care Regenerative Medicine. The fellowship is described as ISSCA's most comprehensive credential to date and as a longer-duration educational offering within ISSCA's existing global physician-education platform. The curriculum is designed to integrate regenerative medicine, emerging biotechnology, longevity medicine, clinical implementation, and artificial intelligence. The AI component aligns with ISSCA AI, ISSCA's physician-controlled clinical-intelligence platform, which is designed to assist participating physicians with structured clinical-data review and workflow support while leaving clinical decision-making with the physician. Management intends for the fellowship to serve as one educational onboarding channel for ISSCA AI, which remains in an early commercialization stage. ISSCA has operated physician-education programs for more than 15 years. Across Cell Stem Cell and its operating businesses, the Company reports that more than 12,000 physicians have been trained and that its network reaches more than 30 countries; these figures are aggregated for context and are not a measure of current paying subscribers to ISSCA AI or of enrollment in the new fellowship. David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc., commented that physicians who will lead this field will need to be fluent across multiple regenerative medicine, biotechnology, and increasingly AI-driven clinical tools, and that the fellowship is designed to deepen relationships with the physician network while creating a more comprehensive credential and an educational pathway into ISSCA AI and related digital tools. ISSCA programs are educational and do not constitute FDA approval, clearance, or authorization of any therapy, product, or software tool.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard